Dialysis is a major financial burden with a large and growing population.

Vascular access is the “lifeline” for hemodialysis patients.1 Vascular access is a major cause of hospitalizations and morbidity in patients with end stage renal disease. Easily obtained and accurate data assessing vascular access could lead to improved outcomes and substantial savings to the healthcare system.

Sonavex dialysis graphic

Learn More

REFERENCES:

    1. Shenoy S, et al. Clinical Trial End Points for Hemodialysis Vascular Access. CJASN March 2018, 13 (3) 490-494
    2. 2019 USRDS Annual Data Report
    3. Fresenius 2011 Annual Report
    4. Fresenius 2018 Annual Report
    5. Fresenius 2019 Annual Report